ATE235549T1 - Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2 - Google Patents

Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2

Info

Publication number: ATE235549T1
Authority: AT; Austria
Prior art keywords: tgf; beta2; antisense oligonucleotides; immunosuppressive effects; treating immunosuppressive
Prior art date: 1993-04-30

Application number

AT99125278T

Other languages

English (en)

Inventor

Georg-Ferdinan Schlingensiepen

Wolfgang Brysch

Karl-Hermann Schlingensiepen

Reimar Schlingensiepen

Ulrich Bogdahn

Original Assignee

Biognostik Ges

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-30

Filing date

1994-04-29

Publication date

2003-04-15

1994-04-29 Application filed by Biognostik Ges filed Critical Biognostik Ges

2003-04-15 Application granted granted Critical

2003-04-15 Publication of ATE235549T1 publication Critical patent/ATE235549T1/de

Links

108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
230000001506 immunosuppresive effect Effects 0.000 title 1
150000007523 nucleic acids Chemical group 0.000 abstract 3
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

AT99125278T 1993-04-30 1994-04-29 Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2 ATE235549T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP93107089		1993-04-30
EP93107849		1993-05-13

Publications (1)

Publication Number	Publication Date
ATE235549T1 true ATE235549T1 (de)	2003-04-15

Family

ID=26133181

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT99125278T ATE235549T1 (de)	1993-04-30	1994-04-29	Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2
AT94916170T ATE211762T1 (de)	1993-04-30	1994-04-29	Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT94916170T ATE211762T1 (de)	1993-04-30	1994-04-29	Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)

Country Status (6)

Country	Link
US (3)	US6455689B1 (de)
JP (2)	JP3555952B2 (de)
AT (2)	ATE235549T1 (de)
AU (1)	AU6794594A (de)
DE (2)	DE69432375T2 (de)
WO (1)	WO1994025588A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU732820B2 (en) *	1995-06-02	2001-05-03	Nexstar Pharmaceuticals, Inc.	High-affinity oligonucleotide ligands to growth factors
US6395494B1 (en)	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
US6884787B2 (en)	2001-07-14	2005-04-26	Isis Pharmaceuticals, Inc.	Antisense modulation of transforming growth factor-beta 3 expression
US5772995A (en)	1994-07-18	1998-06-30	Sidney Kimmel Cancer Center	Compositions and methods for enhanced tumor cell immunity in vivo
DE19613691A1 (de) *	1996-04-05	1997-10-09	Boehringer Ingelheim Int	Arzneimittel für die Behandlung von Tumorerkrankungen
EP0856579A1 (de)	1997-01-31	1998-08-05	BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH	Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
US6117911A (en)	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
DE69919869T2 (de) *	1998-06-10	2005-09-29	Biognostik Gesellschaft für Biomolekulare Diagnostik mbH	Stimulierung des immunsystems
FR2790955B1 (fr)	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
JP2003509030A (ja) *	1999-09-17	2003-03-11	アイシス・ファーマシューティカルス・インコーポレーテッド	トランスフォーミング成長因子−β発現のアンチセンスオリゴヌクレオチド調節
EP1133988A1 (de)	2000-03-11	2001-09-19	Biognostik Gesellschaft für biomolekulare Diagnostik mbH	Mischung enthaldend einen Inhibitor oder Suppressor von einen Gens und eine Moleküle bindende des Expressionprodukt des Gens
US7101543B2 (en)	2000-03-31	2006-09-05	Novarx	Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
PT1456380E (pt) *	2001-11-02	2012-07-23	Giuliani Int Ltd	Inibidores smad7 para o tratamento de doenças do snc
KR20030056538A (ko) *	2001-12-28	2003-07-04	주식회사 웰진	리본형 안티센스 올리고뉴클레오티드에 의한 형질전이성장 인자-β1의 효과적 저해제 개발
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
AU2003299561A1 (en) *	2002-11-18	2004-06-15	Vicuron Pharmaceuticals Inc.	Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
US20070080480A1 (en) *	2003-03-03	2007-04-12	Rick Tabor	Method for reducing the allergenic protein content of natural rubber latex articles
ITRM20030149A1 (it)	2003-04-02	2004-10-03	Giuliani Spa	Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7750142B2 (en) *	2003-04-28	2010-07-06	Isis Pharmaceuticals, Inc.	Modulation of glucagon receptor expression
US7399853B2 (en) *	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
US20050036994A1 (en) *	2003-07-16	2005-02-17	Koichiro Mihara	Compounds and methods for downregulating the effects of TGF-beta
EP2248895B8 (de)	2003-12-19	2016-09-21	Autotelic LLC	Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
US20070196269A1 (en) *	2003-12-19	2007-08-23	Karl-Hermann Schlingensiepen	Pharmaceutical composition
CN1921864A (zh) *	2003-12-24	2007-02-28	西奥斯公司	使用TGF－β抑制剂治疗神经胶质瘤
JP5650367B2 (ja) *	2004-02-27	2015-01-07	アンティセンスファルマゲゼルシャフトミットベシュレンクテルハフツング	医薬組成物
EP1568383A3 (de) *	2004-02-27	2005-11-16	Antisense Pharma GmbH	Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
CN1961003B (zh)	2004-03-31	2013-03-27	健泰科生物技术公司	人源化抗TGF-β抗体
DE102004025881A1 (de) *	2004-05-19	2006-01-05	Beiersdorf Ag	Oligoribonukleotide zur Beeinflussung des Haarwachstums
DK1877070T3 (da) *	2005-05-05	2009-03-02	Antisense Pharma Gmbh	Terapeutisk anvendelse af TGF-beta2 antisense-oligonucleotider
WO2007035771A2 (en) *	2005-09-19	2007-03-29	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Modulation of glucagon receptor expression
EP1948675B1 (de)	2005-10-25	2014-07-30	The Johns Hopkins University	Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen
US8454952B2 (en)	2006-03-13	2013-06-04	The Johns Hopkins University	Augmentation of endothelial thromboresistance
DK2083863T3 (da)	2006-10-03	2015-06-22	Genzyme Corp	Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
US8822425B2 (en) *	2008-11-14	2014-09-02	Antisense Pharma Gmbh	Dosage of oligonucleotides suitable for the treatment of tumors
WO2011088148A1 (en) *	2010-01-12	2011-07-21	Isis Pharmaceuticals, Inc.	Modulation of transforming growth factor-beta 1 expression
ME02464B (de)	2010-03-12	2017-02-20	Genzyme Corp	Kombinationstherapie zur Behandlung von Brustkrebs
EP2580326A1 (de)	2010-06-11	2013-04-17	Antisense Pharma GmbH	Verfahren zur selektiven oligonukleotidmodifikation
CA2823154A1 (en)	2010-12-27	2012-07-05	Lsip, Llc	Ips cells and method for generating same
US20140308275A1 (en)	2011-07-27	2014-10-16	Inserm (Institut National De La Sante Et De La Recherche Medicale	Methods for diagnosing and treating myhre syndrome
ES2796556T3 (es)	2011-09-20	2020-11-27	Ionis Pharmaceuticals Inc	Modulación antisentido de la expresión de GCGR
WO2013062544A1 (en)	2011-10-26	2013-05-02	Seattle Children's Research Institute	Cysteamine in the treatment of fibrotic disease
EP2799537B1 (de)	2011-12-28	2021-09-22	Kyoto Prefectural Public University Corporation	Normalisierung der züchtung von hornhautendothelzellen
KR102338833B1 (ko)	2012-02-06	2021-12-13	인히브릭스, 인크.	Cd47 항체 및 그 사용 방법
DK2978844T3 (da) *	2013-03-27	2020-11-16	Isarna Therapeutics Gmbh	Modificerede tgf-beta2-oligonukleotider
BR112015024760B8 (pt)	2013-03-27	2022-06-21	Isarna Therapeutics Gmbh	Oligonucleotídeo antissenso, composição farmacêutica e uso dos mesmos na prevenção e/ou tratamento de uma doença oftálmica
CN105378083B (zh)	2013-03-27	2018-09-21	伊萨纳治疗有限公司	修饰的TGF-β寡核苷酸
CA2927898C (en)	2013-10-31	2021-11-16	Kyoto Prefectural Public University Corporation	Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10882903B2 (en)	2015-05-18	2021-01-05	Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods and compositions for treating an alphavirus infection
US9758786B2 (en)	2016-02-09	2017-09-12	Autotelic, Llc	Compositions and methods for treating pancreatic cancer
KR20180103816A (ko)	2016-02-09	2018-09-19	오토텔릭 엘엘씨	췌장암을 치료하기 위한 조성물과 방법
WO2022060208A1 (ko)	2020-09-21	2022-03-24	오토텔릭바이오 주식회사	안티센스 올리고뉴클레오타이드
EP4720299A1 (de) *	2023-06-05	2026-04-08	GMP Biotechnology Limited	Tgfb2-irf5-therapeutika gegen krebs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU626524B2 (en) *	1987-05-29	1992-08-06	Bristol-Myers Squibb Company	Cloning and expression of simian transforming growth factor- beta 1
US5221620A (en) *	1987-10-06	1993-06-22	Oncogen	Cloning and expression of transforming growth factor β2
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
US5525468A (en) *	1992-05-14	1996-06-11	Ribozyme Pharmaceuticals, Inc.	Assay for Ribozyme target site
US5596072A (en) *	1992-08-21	1997-01-21	Schering Corporation	Method of refolding human IL-13
US5464945A (en) *	1992-08-28	1995-11-07	Hoffmann-La Roche Inc.	Oligonucleotide probes specific for the human alpha satellite locus

1994
- 1994-04-29 AT AT99125278T patent/ATE235549T1/de active
- 1994-04-29 DE DE69432375T patent/DE69432375T2/de not_active Expired - Lifetime
- 1994-04-29 JP JP52389894A patent/JP3555952B2/ja not_active Expired - Lifetime
- 1994-04-29 DE DE69429617T patent/DE69429617T2/de not_active Expired - Lifetime
- 1994-04-29 AU AU67945/94A patent/AU6794594A/en not_active Abandoned
- 1994-04-29 US US08/535,249 patent/US6455689B1/en not_active Expired - Lifetime
- 1994-04-29 AT AT94916170T patent/ATE211762T1/de active
- 1994-04-29 WO PCT/EP1994/001362 patent/WO1994025588A2/en not_active Ceased
2002
- 2002-05-16 US US10/146,058 patent/US20030040499A1/en not_active Abandoned
2003
- 2003-06-30 JP JP2003188524A patent/JP3600831B2/ja not_active Expired - Lifetime
2006
- 2006-12-29 US US11/647,586 patent/US7667027B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6455689B1 (en)	2002-09-24
JP3600831B2 (ja)	2004-12-15
JP3555952B2 (ja)	2004-08-18
DE69429617D1 (de)	2002-02-14
US20080214483A1 (en)	2008-09-04
WO1994025588A3 (en)	1994-12-22
JP2004024264A (ja)	2004-01-29
ATE211762T1 (de)	2002-01-15
US20030040499A1 (en)	2003-02-27
US7667027B2 (en)	2010-02-23
JPH08509370A (ja)	1996-10-08
DE69429617T2 (de)	2002-08-22
AU6794594A (en)	1994-11-21
DE69432375D1 (de)	2003-04-30
DE69432375T2 (de)	2004-02-12
WO1994025588A2 (en)	1994-11-10

Legal Events

Date

Code

Title

Description

2003-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1008649

Country of ref document: EP

Publication	Publication Date	Title
ATE235549T1 (de)	2003-04-15	Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2
EP1762619A3 (de)	2007-05-09	Multi-tumor abweichende wachstumsgene
DE69425890D1 (de)	2000-10-19	Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
FI951612A0 (fi)	1995-04-05	Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia
DE3854936D1 (de)	1996-03-07	Verfahren zur optimierten "Rete"-Musteranpassung in mustergeführten, regelbasierten, künstlichen Intelligenz-Produktionssystemen
CA2213991A1 (en)	1997-07-10	Cold-inducible promoter sequence
CA2236166A1 (en)	1997-06-05	Enhancer-increased gene expression in plants
EP0702694A4 (de)	2000-10-04	$i(PSEUDOMONAS SYRINGAE) pv. $i(SYRINGAE hrpY)-GEN
EP1008649A3 (de)	2000-07-12	Antisense Oligonukleotide zur Behandlung von Immunosuppressive Wirkungen von TGF-beta2
DK2256205T3 (da)	2013-07-08	Porphorymonas gingivalis-polypeptider og -polynukleotider
ATE137806T1 (de)	1996-05-15	Verfahren zur identifizierung von bakterien
DE69839178D1 (de)	2008-04-10	Gene, die für proteine mit transglykolysierungsaktivität kodieren.
PL317046A1 (en)	1997-03-03	Endotransglycosidase to tomato xyloglucane
ATE296886T1 (de)	2005-06-15	Männliche fertilität vermittelnde nukleotidsequenzen und verfahren zu ihrer verwendung
AU6144294A (en)	1994-09-14	Plant virus resistance conferring polyribozyme and resistant plants producing same
DE59611131D1 (de)	2004-12-09	Acarbose-Biosynthesegene aus Actinoplanes sp., Verfahren zu ihrer Isolierung sowie ihrer Verwendung
DE69432925D1 (de)	2003-08-14	Wachtumsfaktor aus der harp-reihe, verfahren zu ihrer herstellung und verwendungen davon
ES2109373T3 (es)	1998-01-16	Nueva proteina inhibidora de trombina a partir de garrapatas.
CA2203801A1 (en)	1996-05-09	Nucleotide sequences mediating male fertility and method of using same
CA2419038A1 (en)	2003-02-11	Nucleic acid and protein increasing expression levels under salt stress
TH52857A (th)	2002-09-04	แบคทีเรียของสกุล Bacillus และโปรตีนสำหรับฆ่าแมลง
RU98123505A (ru)	2000-11-20	Толлоидподобный ген млекопитающих и кодируемый им протеин